Evidence map›Paper›PMID 35544131›Full record

ArticleJAMA surgery2022

Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.

Stijn Franssen, Kevin C Soares, Joshua Samuel Jolissaint, Diamantis I Tsilimigras, Stefan Buettner, Sorin Alexandrescu, Hugo Marques, Jorge Lamelas, Luca Aldrighetti, T Clark Gamblin and 15 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in JAMA surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06739252 (Perioperative Treatment of High-risk Resectable Cholangiocarcinoma With Hepatic Arterial Infusion Chemotherapy), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06739252 phase2terminatednot on this mapstarted 2024, after this paper: background citation

Perioperative Treatment of High-risk Resectable Cholangiocarcinoma With Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Atezo/Bevacizumab: a Multicenter Phase II Study (NeoBrave CCA)

TypeinterventionalSponsorPeking UniversityRan2024 to 2025Enrolled1ConditionsIntrahepatic Cholangiocarcinoma (Icc), Perihilar CholangiocarcinomaArmsGemcitabine Oxaliplatin and 5FU
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 7 countries.

Stijn FranssenDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Kevin C SoaresDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Joshua Samuel JolissaintDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Diamantis I TsilimigrasDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus.
Stefan BuettnerDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Sorin AlexandrescuDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
Hugo MarquesDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Jorge LamelasDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Luca AldrighettiDepartment of Surgery, Ospedale San Raffaele, Milan, Italy.
T Clark GamblinDepartment of Surgery, Medical College of Wisconsin, Milwaukee.
Shishir K MaithelDepartment of Surgery, Emory University School of Medicine, Atlanta, Georgia.
Carlo PulitanoDepartment of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
Georgios A MargonisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Matthew J WeissDepartment of Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Todd W BauerDepartment of Surgery, University of Virginia, Charlottesville.
Feng ShenDepartment of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
George A PoultsidesDepartment of Surgery, Stanford University, Stanford, California.
James Wallis MarshDepartment of Surgery, West Virginia University Health Sciences Center, Morgantown.
Andrea CercekDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Nancy KemenyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael D'AngelicaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Timothy M PawlikDepartment of Surgery, The Ohio State University Wexner Medical Center, Columbus.
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Bas Groot KoerkampDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Memorial Sloan Kettering Cancer Center · USErasmus MC Cancer Institute · NLHospital Curry Cabral · PTThe Ohio State University Wexner Medical Center · USDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · USEmory University · USInstitutul Clinic Fundeni · ROIRCCS Ospedale San Raffaele · ITMedical College of Wisconsin · USRoyal Prince Alfred Hospital · AUSecond Military Medical University · CNStanford University · USUniversity of Virginia · USWest Virginia University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Importance: Intrahepatic cholangiocarcinoma (iCCA) is often multifocal (ie, satellites or intrahepatic metastases) at presentation. Objective: To compare the overall survival (OS) of patients with multifocal iCCA after hepatic arterial infusion pump (HAIP) floxuridine chemotherapy vs resection. Design, Setting, and Participants: In this cohort study, patients with histologically confirmed, multifocal iCCA were eligible. The HAIP group consisted of consecutive patients from a single center who underwent HAIP floxuridine chemotherapy for unresectable multifocal iCCA between January 1, 2001, and December 31, 2018. The resection group consisted of consecutive patients from 12 centers who underwent a curative-intent resection for multifocal iCCA between January 1, 1990, and December 31, 2017. Resectable metastatic disease to regional lymph nodes and previous systemic therapy were permitted. Patients with distant metastatic disease (ie, stage IV), those who underwent resection before starting HAIP floxuridine chemotherapy, and those who received a liver transplant were excluded. Data were analyzed on September 1, 2021. Main Outcomes and Measures: Overall survival in the 2 treatment groups was compared using the Kaplan-Meier method and log-rank test. Results: A total of 319 patients with multifocal iCCA were included: 141 in the HAIP group (median [IQR] age, 62 [53-70] years; 79 [56.0%] women) and 178 in the resection group (median [IQR] age, 60 [50-69] years; 91 [51.1%] men). The HAIP group was characterized by a higher percentage of bilobar disease (88.0% [n = 124] vs 34.3% [n = 61]), larger tumors (median, 8.4 cm vs 7.0 cm), and a higher proportion of patients with 4 or more lesions (66.7% [94] vs 24.2% [43]). Postoperative mortality after 30 days was 0.8% (95% CI, 0.0%-2.1%) in the HAIP group vs 6.2% (95% CI, 2.3%-9.7%) in the resection group (P = .01). The median OS for HAIP was 20.3 months vs 18.9 months for resection (P = .32). Five-year OS in patients with 2 or 3 lesions was 23.7% (95% CI, 12.3%-45.7%) in the HAIP group vs 25.7% (95% CI, 17.9%-37.0%) in the resection group. Five-year OS in patients with 4 or more lesions was 5.0% (95% CI, 1.7%-14.3%) in the HAIP group vs 6.8% (95% CI, 1.8%-25.3%) in the resection group. After adjustment for tumor diameter, number of tumors, and lymph node metastases, the hazard ratio of HAIP vs resection was 0.75 (95% CI, 0.55-1.03; P = .07). Conclusions and Relevance: This cohort study found that patients with multifocal iCCA had similar OS after HAIP floxuridine chemotherapy vs resection. Resection of multifocal intrahepatic cholangiocarcinoma needs to be considered carefully given the complication rate of major liver resection; HAIP floxuridine chemotherapy may be an effective alternative option.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaLiver NeoplasmsBile Ducts, IntrahepaticCohort StudiesFemaleFloxuridineHumansInfusion PumpsMaleMiddle AgedRetrospective StudiesFloxuridine

Identifiers

PMID35544131
PMCPMC9096688
OpenAlexW4280522438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.